Impact of a direct-to-consumer information campaign on prescription patterns for overactive bladder

Abstract

BackgroundDirect-to-consumer information (DTCI) campaign is a new medium to inform and empower patients in their decision-making without directly promoting specific drugs. However, little is known about the impact of DTCI campaigns, expanding rapidly in developed countries, on changes in prescription patterns. We sought to determine whether a DTCI campaign on overactive bladder increases the prescription rate for overactive bladder treatment drugs.MethodsWe performed a 3-year retrospective cohort study of 1332 participants who were diagnosed overactive bladder but not prescribed treatment drugs prior to the examined DTCI campaign (exposure), using the health insurance claims dataset of the Japan Medical Data Center (November 19, 2010 to November 18, 2013). The DTCI campaign for overactive bladder included television, Internet, and print advertising (November 19, 2011 to December 22, 2011). We divided the study period into Pre-Campaign Year (2010–2011), Year 1 (2011–2012), and Year 2 (2012–2013). Each year began on November 19 and included Period 1 (weeks 1–5) through Period 10 (weeks 46–50). The main outcome was first-time prescription of the treatment drug for each patient, measured by 5-week periods. Using Period 10 in the Pre-Campaign Year as the referent period, we applied the Cox proportional hazard model for each period. Additionally, we performed the interrupted time series analysis (ITSA) for the first-time prescription rate per 5-week period.ResultsFollowing the DTCI campaign, patients were about seven times more likely to receive a first prescription of a treatment drug during Period 4 in Year 1 (hazard ratio 7.09; 95% CI, 2.11–23.8; p-value<.01) compared with the reference period. Similar increases were also observed for subsequent Periods 5 and 6 in Year 1. The ITSA confirmed the DTCI campaign impact on the level of prescription rate (one-time increase in the regression-intercept) that increased by 1128.1 [per standardized 100,000 persons] (p < .05) during Period 4 in Year 1.ConclusionsThe examined DTCI campaign appeared to increase the prescription rate among patients with overactive bladder for 15 weeks with a 15-week delay. Clinical outcomes of the patients with targeted diseases need to be monitored after DTCI campaigns by a future study.Electronic supplementary materialThe online version of this article (10.1186/s12913-018-3147-1) contains supplementary material, which is available to authorized users.

Indirect health effects of the COVID-19 pandemic in Kenya: a mixed methods assessment

“…In these models, the time since start of study was entered as a continuous variable indicating the month since start whereas intervention periods is a dummy variable indicating pre-intervention "0", otherwise "1" [20,22]. These analysis were performed in STATA version 16 [23].…”

Recommendations for the ethical conduct of vaccination awareness campaigns by biopharmaceutical companies

“…The number of DA campaigns has grown rapidly in the US, 15 as well as in countries where DTCA is forbidden. 16–18 DA campaigns are part of companies’ strategies to encourage patients to seek help for medical conditions for which prescription drugs are available. 5 There is evidence that patient requests for medication subsequent to DA campaigns may influence doctors’ prescription behavior and this raises concerns that warrant ethical recommendations.…”

“…Arguments made in favor of DA campaigns include the promotion of patient autonomy and improved public health thanks to increased diagnosis, better management and treatment of rare, serious or debilitating diseases, as well as de-stigmatization of diseases (e.g., HIV) or embarrassing symptoms (e.g., erectile dysfunction). 15 , 16 , 20–22 The Israeli Ministry of Health established regulations regarding DA campaigns to specifically empower consumers by providing them with information about the availability of treatments for diseases (medications or preventive treatments) in a manner that does not involve the promotion of a particular commercial product. 21 …”

“…For government, savings in healthcare-associated costs may also be achieved. In the case of industry-sponsored campaigns, an ethical tension exists in that a successful DA campaign is likely to increase prescribing by healthcare professionals 16 and runs a risk of being perceived as disguised promotion.…”

Regulating Product Recall Compliance in the Digital Age: Evidence from the “Safe Cars Save Lives” Campaign

“…For example, Wallington et al (2018) showed that the introduction of a mass media campaign was associated with increased consumer information search, displayed by high click-through rates to a website and more referrals to medical centers. Relatedly, Zaitsu et al (2018) found that patients were more likely to obtain a first prescription of a treatment following a direct-to-consumer advertising campaign designed to educate them and provide resources about health-related decisions. The positive impact of advertising initiatives by firms may even spill over to the category level, as Wosińska (2005) noted that advertising by a brand increased consumer drug therapy compliance of its rival brands’ products.…”